Negocie Vir Biotechnology VIR

Gráfico VirBiotechnology ao vivo

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

VirBiotechnology news

Últimas notícias

Mostrar mais
Noah Lee 2025 Sep 05, 14:20

US Job Growth Slows, Unemployment Rises: Rate Cut Outlook Intensifies

Emma Rose 2025 Sep 05, 14:20

Global Market Overview: Weak Nonfarm Data, Gold Hits Highs, OPEC+ Considers Output Hike

Emma Rose 2025 Sep 05, 13:20

US Job Growth Slows, Unemployment Rises: Fed Rate Cut Expectations Surge

Sophia Claire 2025 Sep 05, 12:20

Tesla Proposes a Potential $1 Trillion Compensation Plan for Elon Musk

Emma Rose 2025 Sep 05, 12:20

August Non-Farm Payroll Report: Will it Trigger a Fed Rate Cut?

Sophia Claire 2025 Sep 05, 11:20

US Non-Farm Payrolls August: Impact on Fed Rate Decision

Emma Rose 2025 Sep 05, 10:20

US Job Growth Slowdown: Fed Rate Cut Outlook Intensifies

Liam James 2025 Sep 05, 08:20

Gold Soars to Record Highs: Analysis and Future Outlook

Info

Spread

0.05

Spread (%)

0.9597 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercado aberto

Sexta-feira

13:31 - 19:59

Segunda-feira

13:31-19:59

Terça-feira

13:31-19:59

Quarta-feira

13:31-19:59

Quinta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

765427200

Ações em circulação

138916000

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

Data Ex-Dividendos

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-4.01

Saiba mais sobre este instrumento

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):
Instrumentos relacionados

latest_education_articles

Mostrar mais
Trustpilot